Drug Trial Radar · NCT05718258
A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function
Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Jan 18, 2023
Primary completion
Jan 29, 2024
Study completion Jan 29, 2024
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel, Phase 1, four arm, open-label, single dose, multicenter study to evaluate the impact of hepatic impairment on venglustat exposure following treatment with venglustat. The purpose of this study is to assess the effect of mild, moderate, and severe hepatic impairment on PK, safety, and tolerability of venglustat compared with normal hepatic function in male and female participants aged 18 to 79 years. Study details include: * The total study duration per participant will be up to 42 days, including up to 21 days for screening and approximately 21 days from institutionalization to the end of study (EOS). * Institutionalization is mandatory until the activities on D5 have been completed. * Each participant will receive a single dose of venglustat. * For hepatically impaired participants there will be a screening visit, a multi-day institutionalization visit, and 7 site visits after D5 discharge, including the end of study (EOS) visit. * For healthy volunteers there will be a screening visit, a multi-day institutionalization visit and 3 site visits after D5 discharge, including the end of study (EOS) visit.
Conditions
- Hepatic Function Abnormal
Interventions
Venglustat (GZ402671)Drug
Pharmaceutical form: tablet Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum venglustat plasma concentration observed (Cmax)Time frame: Baseline to Day 20
- Area under the plasma concentration versus time curve extrapolated to infinity (AUC)Time frame: Baseline to Day 20
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Inland Empire Liver Foundation Site Number : 8400004
Rialto, California
Clinical Pharmacology of Miami Site Number : 8400002
Miami, Florida
Nucleus Network Site Number : 8400001
Saint Paul, Minnesota
Volunteer Research Group-NOCCR Site Number : 8400003
Knoxville, Tennessee
American Research Corporation Site Number : 8400005
San Antonio, Texas
Investigational Site Number : 2760001
Kiel, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.